Source: IGF Oncology, LLC
US Patent No. 7,811,982 and family covering 765IGF-MTX
IGF Oncology owns U.S. Patent No. 7,811,982, which claims broadly
variants of IGF-1 conjugated to anti-cancer chemotherapeutic agents. The
variants of IGF-1 are those with reduced binding affinity for the
soluble IGF-binding proteins. The claims encompass but do not name or
disclose the 765IGF variant and the 765IGF-MTX conjugate. Methotrexate
is specifically claimed as a chemotherapeutic agent portion of the
conjugate. This patent has a 770 day extension for USPTO delays, and so
expires in about December 2026, with further extensions of time
available for time in clinical trials and FDA approval. Other patents in
this family are US Patent Nos. 9,011,880 and 8,501,906. We have issued
foreign patents in this family in Canada, UK, France, Germany, and
Japan.
U.S. Patent No. 9,675,671 and family covering 765IGF-MTX and 765EGF-bendamustine
This patent is directed to the 765IGF protein and the 765EGF
protein, which are our proprietary variants of IGF-1 and EGF
respectively, and it covers other cytokines with the same or related
N-terminal segment as is used in 765IGF and 765EGF. This patent will
expire on January 12, 2035, with extensions possible for time spent in
clinical trials and FDA review. An allowed divisional U.S. patent claims
the chemotherapeutic conjugates to 765IGF and 765EGF, specifically
including 765IGF-MTX and 765EGF-bendamustine. Foreign patent
applications in this family are filed in Japan, India, Korea, Canada,
Australia, and Europe.
U.S. Patent Nos. 8,017,102 and family
This patent claims conjugates of toxins (as contrasted with
chemotherapeutic agents) with variants of IGF-1 having reduced binding
affinity for the soluble IGF-binding proteins. The other patent in this
family is U.S. Patent No. 8,920,777. We have issued foreign patents in
UK, Germany, and France in this family.
U.S. Provisional patent application 62/509,150, covering method of
treatment for using 765IGF-MTX to treat myelodysplastic syndrome.
This provisional patent application will be converted to a regular
U.S. utility patent application and international patent application in
2018. When patents are issued on these, they would have patent term
extending to at least 2038.
Patent applications to be filed to cover CPE-54 specifically as a composition, and a method of treating cancer
We intend to file patent applications for these two new inventions
in 2018. Issued patents based on these would expire in 2038 most likely.
These will be assigned to IGF Oncology, LLC.
U.S. Patent No. 8,664,184, and family, licensed from Yale University
and the Univ. of Arkansas, covering use of CPE to treat ovarian and
uterine cancers and peritoneally located cancers
This patent has claims covering use of CPE to treat ovarian and
uterine cancers with CPE or a variant thereof, optionally by peritoneal
administration. Other patents in the family are U.S. Patent Nos.
9,702,010, and 8,247,371. They expire on October 12, 2025, with possible
extension for time in clinical trials and for FDA approval. U.S. Patent
No. 8,247,371 also has a 638 day extension for USPTO delays. These are
all licensed from Yale University. U.S. Patent No. 7,927,795 is for
diagnosing or monitoring ovarian cancer by detecting overexpression of
claudin-3 or -4 or many other genes. It has the same inventor, Dr.
Santin, and is assigned to the Univ. of Arkansas and licensed from them.
No comments:
Post a Comment